RecruitingPhase 2NCT06618534
Azithromycin for Meningococcal Carriage
Effectiveness of Azithromycin in Eradicating Nasopharyngeal Carriage of N. Meningitidis
Sponsor
Emory University
Enrollment
1,120 participants
Start Date
Nov 12, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
Eligibility
Min Age: 18 YearsMax Age: 25 Years
Inclusion Criteria2
- Able to provide their own informed consent and understand study procedures
- Undergraduate and graduate students attending Emory University affiliated campuses who reside in university affiliated housing (for undergraduate/graduate) or in off-campus housing (undergraduates).
Exclusion Criteria5
- University faculty and staff
- Currently pregnant or breast feeding
- History of immediate or moderate-to-severe allergic reactions to azithromycin
- Individuals who have taken systemic antibiotics for any reason in the 30 days prior to enrollment
- Individuals with any symptoms of acute illness at the time of screening
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAzithromycin
A standard dose of azithromycin (500 mg) will be delivered by oral route.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06618534